Cargando…
Practical considerations for the use of mTOR inhibitors
Immunosuppressive therapy after kidney transplantation is based on calcineurin inhibitors (CNI). In most cases CNI therapy is combined with mycophenolate and steroids. In spite of good short-term results this therapy is associated with long-term toxicities, graft loss and patient death. Therefore, a...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4895281/ https://www.ncbi.nlm.nih.gov/pubmed/27293552 http://dx.doi.org/10.1186/s13737-015-0029-5 |
_version_ | 1782435817821569024 |
---|---|
author | Diekmann, Fritz Campistol, Josep M. |
author_facet | Diekmann, Fritz Campistol, Josep M. |
author_sort | Diekmann, Fritz |
collection | PubMed |
description | Immunosuppressive therapy after kidney transplantation is based on calcineurin inhibitors (CNI). In most cases CNI therapy is combined with mycophenolate and steroids. In spite of good short-term results this therapy is associated with long-term toxicities, graft loss and patient death. Therefore, alternative immunosuppressive strategies are needed that combine excellent efficacy with low incidences of long-term adverse outcomes. This review focuses on the strategies based on mTOR- inhibitors in combination with minimized exposure to CNI. |
format | Online Article Text |
id | pubmed-4895281 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-48952812016-06-10 Practical considerations for the use of mTOR inhibitors Diekmann, Fritz Campistol, Josep M. Transplant Res Review Immunosuppressive therapy after kidney transplantation is based on calcineurin inhibitors (CNI). In most cases CNI therapy is combined with mycophenolate and steroids. In spite of good short-term results this therapy is associated with long-term toxicities, graft loss and patient death. Therefore, alternative immunosuppressive strategies are needed that combine excellent efficacy with low incidences of long-term adverse outcomes. This review focuses on the strategies based on mTOR- inhibitors in combination with minimized exposure to CNI. BioMed Central 2015-12-22 /pmc/articles/PMC4895281/ /pubmed/27293552 http://dx.doi.org/10.1186/s13737-015-0029-5 Text en © Diekmann and Campistol. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Review Diekmann, Fritz Campistol, Josep M. Practical considerations for the use of mTOR inhibitors |
title | Practical considerations for the use of mTOR inhibitors |
title_full | Practical considerations for the use of mTOR inhibitors |
title_fullStr | Practical considerations for the use of mTOR inhibitors |
title_full_unstemmed | Practical considerations for the use of mTOR inhibitors |
title_short | Practical considerations for the use of mTOR inhibitors |
title_sort | practical considerations for the use of mtor inhibitors |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4895281/ https://www.ncbi.nlm.nih.gov/pubmed/27293552 http://dx.doi.org/10.1186/s13737-015-0029-5 |
work_keys_str_mv | AT diekmannfritz practicalconsiderationsfortheuseofmtorinhibitors AT campistoljosepm practicalconsiderationsfortheuseofmtorinhibitors |